Pan Cancer T

Pan Cancer T develops next-generation T-cell therapies for hard-to-treat solid tumors. The company focuses on highly specific cancer targets and strengthens T cells so they remain active longer in fighting tumours. This matters because existing cell therapies still have limited effect in solid cancers. With the investment from InnovationQuarter Capital, Pan Cancer T can complete preclinical studies, advance CMC activities, and continue developing its pipeline.